IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MORGANTI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.400
NA - Nord America 903
AS - Asia 856
SA - Sud America 64
AF - Africa 34
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.275
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 1.384
US - Stati Uniti d'America 845
CN - Cina 324
IT - Italia 294
GB - Regno Unito 208
SG - Singapore 171
SE - Svezia 155
IN - India 107
IE - Irlanda 67
RU - Federazione Russa 64
HK - Hong Kong 43
FR - Francia 42
ID - Indonesia 36
BR - Brasile 35
JP - Giappone 32
ES - Italia 31
NL - Olanda 30
TR - Turchia 30
MX - Messico 28
CA - Canada 27
VN - Vietnam 23
KR - Corea 19
FI - Finlandia 18
PL - Polonia 16
EG - Egitto 15
AT - Austria 14
BE - Belgio 13
CH - Svizzera 13
AU - Australia 12
PK - Pakistan 10
LB - Libano 9
CO - Colombia 8
UA - Ucraina 8
MY - Malesia 7
PE - Perù 7
PT - Portogallo 7
ZA - Sudafrica 7
DK - Danimarca 6
GR - Grecia 6
PH - Filippine 6
AM - Armenia 5
AR - Argentina 5
TH - Thailandia 5
VE - Venezuela 5
IL - Israele 4
IR - Iran 4
JO - Giordania 4
NZ - Nuova Zelanda 4
RO - Romania 4
SA - Arabia Saudita 4
TN - Tunisia 4
TW - Taiwan 4
BG - Bulgaria 3
CL - Cile 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
HR - Croazia 2
LT - Lituania 2
MA - Marocco 2
NO - Norvegia 2
PA - Panama 2
SC - Seychelles 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
EC - Ecuador 1
EE - Estonia 1
HN - Honduras 1
LA - Repubblica Popolare Democratica del Laos 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NG - Nigeria 1
Totale 4.275
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.294
Southend 159
Chandler 148
Singapore 102
Milan 101
Dublin 63
Santa Clara 59
Ashburn 41
New York 38
Princeton 38
Council Bluffs 33
Beijing 32
Shanghai 30
Fairfield 28
Hong Kong 27
Ann Arbor 23
Jakarta 23
Istanbul 22
Cambridge 21
Hyderabad 19
Toronto 19
Los Angeles 18
Helsinki 17
Bengaluru 16
Rome 15
Berlin 14
Wilmington 14
Grafing 13
Houston 13
Des Moines 12
Chennai 11
Barcelona 10
Brussels 10
Fuzhou 10
Phoenix 10
Seoul 10
Curitiba 9
Munich 9
Nuremberg 9
Vienna 9
Cairo 8
Gdansk 8
London 8
Nanjing 8
Redwood City 8
Seattle 8
Wuhan 8
Boston 7
San Diego 7
Bologna 6
Cape Town 6
Fremont 6
Hangzhou 6
Buffalo 5
Delhi 5
Kuala Lumpur 5
Lanester 5
Madrid 5
Mexico City 5
Rho 5
San Jose 5
Tianjin 5
Tokyo 5
Valencia 5
Woodbridge 5
Yerevan 5
Zhengzhou 5
Amman 4
Beersheba 4
Bergamo 4
Bogotá 4
Buenos Aires 4
Bühl 4
Cuauhtémoc 4
Dearborn 4
Guangzhou 4
Lima 4
Manchester 4
Nizhniy Novgorod 4
Paris 4
Pordenone 4
Porto 4
Predazzo 4
Pune 4
Seregno 4
Taipei 4
Turin 4
Ambler 3
Amsterdam 3
Athens 3
Auckland 3
Bari 3
Bishkek 3
Boardman 3
Brisbane 3
Cantù 3
Central District 3
Falls Church 3
Florence 3
Gainesville 3
Totale 2.832
Salva come PNG Salva come JPEG
Nome #
Biologic therapy for advanced breast cancer : recent advances and future directions 466
Margetuximab for the treatment of HER2-positive metastatic breast cancer 419
Antibody–drug conjugates in solid tumors: a look into novel targets 226
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 178
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 158
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 153
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 143
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 138
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 134
Master protocols in immuno-oncology : Do novel drugs deserve novel designs? 133
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 130
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 130
Combinations using checkpoint blockade to overcome resistance 125
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 125
What therapies are on the horizon for HER2 positive breast cancer? 124
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 123
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data 118
HER2-Low Breast Cancer: Pathological and Clinical Landscape 115
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 115
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 108
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 106
Clinical development and current role of margetuximab for the treatment of breast cancer 104
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 100
I diritti dei morenti in diversi setting di cura al tempo del Covid-19. Uno studio retrospettivo trasversale sulle opinioni degli operatori sanitari. 96
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life 95
Optimizing treatment strategy in early breast cancer: less is more, or more is better? 95
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 93
Characterization of low HER2 expressions in de-novo metastatic breast cancer 87
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 82
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist 81
COVID-19 related risk in patients enrolled in early-phase clinical trials 79
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 7
null 6
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls 6
EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials 4
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 3
null 3
PARP Inhibitors for Breast Cancer Treatment 1
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 1
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 1
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 1
Totale 4.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017 0 0 0 0 0 0 0 0 10 6 1 0
2020/2021313 23 16 5 10 14 14 17 23 51 52 49 39
2021/2022586 41 48 22 33 56 59 26 51 90 40 48 72
2022/2023766 77 79 76 61 80 107 28 39 98 34 58 29
2023/20241.467 33 43 41 68 139 82 205 174 98 171 210 203
2024/20251.233 174 217 162 191 119 72 47 158 93 0 0 0
Totale 4.412